The dynamics of the levels of antibodies to TSH receptor of the patients with diffuse toxic goiter with autoimmune ophthalmopathy during the antithyroid therapy
Vol. 18 No. 4 (2013), ORIGINAL PAPERS
Vol. 18 No. 4 (2013)

The dynamics of the levels of antibodies to TSH receptor of the patients with diffuse toxic goiter with autoimmune ophthalmopathy during the antithyroid therapy

ORIGINAL PAPERS
Published December 20, 2013
V.A. Olijnyk
ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України»
Y.V. Buldygina
ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України»
G.N. Terekhova
ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України»
S.L. Shlyakhtych
ДУ «Інститут ендокринології та обміну речовин ім. В.П. Комісаренка НАМН України»
pdf (Українська)

Keywords

thyroid gland, diffuse toxic goiter, endocrine ophthalmopathy, antibodies to TSH receptor.

How to Cite

Olijnyk, V., Buldygina, Y., Terekhova, G., & Shlyakhtych, S. (2013). The dynamics of the levels of antibodies to TSH receptor of the patients with diffuse toxic goiter with autoimmune ophthalmopathy during the antithyroid therapy. Endokrynologia, 18(4), 5-10. Retrieved from https://endokrynologia.com.ua/index.php/journal/article/view/354
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver

Download Citation

Endnote/Zotero/Mendeley (RIS) BibTeX

Abstract

The aim of the research was to study the dynamics of the levels of antibodies to TSH receptor (AB rTSH) among patients with diffuse toxic goiter (DTG) and endocrine ophthalmopathy during antithyroid therapy. With this purpose, 147 patients with diffuse toxic goiter were followed up, including 112 ones without
manifestations of ophthalmopathy and 35 patients with DTG and ophthalmopathy. The levels of TSH, thyroid hormones and AB rTSH were determined during antithyroid therapy. The method of immunoenzymic analysis was used for testing AB rTSH in blood serum by means of standard kits from «Medizim» (England). In the process of pharmacotherapy, a decrease in AB rTSH levels in both groups of patients was reported. An analysis of the dynamics of changes
in AB rTSH levels has shown that their levels among patients with DTG and ophthalmopathy significantly exceeded the indices for the group without ophthalmopathy both at the beginning of therapy and after 6 months.

pdf (Українська)

References

1. Advances in Thyroid Eye Disease. International Satellite Symposium of 25 Annual Meeting of the Thyroid Assotiation // Thyroid. 1998, 8, 407-471.
2. Bahn R.S., Dutton C.M., Natt N. et al. // J.Clin. Endocrinol.Metab. 1998, 83, 998-1002.
3. Свириденко Н.Ю., Лихванцева В.Г., Беловалова И.М. и др. Антитела к рецептору ТТГ как предикторы тяжести и исходов эндокринной офтальмопатии у пациентов с болезнью Грейвса // Пробл. эндокринол. 2011, №2, 23-26. (Sviridenko N.Yu., Likhvantseva V.G., Belovalova I.M. et al. Antibodies to TTH receptor as predictors of severity and outcomes of endocrine ophthalmopathy in patients with Graves desease // Problems of Endocrinology. 2011, N 2, 23-26).
4. Heufelder A.E. Patogenesis of ophthalmopathy in autoimmune thyroid disease // Rev. Endocr. Metabol. Disoders. 2000, N1, 87-95.
5. Bann R.S. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves ophtalmopathy // J. Endocrinol. Invest. 2004, N3, 216-220.
6. Martins J.M., Furlanetto R.P., Olivera L.M. et al. Comparison of practical methods of urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with ophtalmopathy // Clin. Endocrinol. 2004, 60, 726-733.
7. Smith T.J., Koumas L. et al. Orbital fibroblast geterogeneity may determine the clinical presentation of thyroid-assotiated ophtalmopathy // J. Clin. Endocrinol. Metab. 2002, 87, 385-392.
8. Smith T.J. Novel aspects of orbital fibroblast pathology // J. Clin. Invest. 2005, 27, 246-253.
9. Valyasevi R.W., Erickson D.Z. et al. Differentiation of human orbital preadypocyte fibroblasts induces expression of functional thyroid receptor // J. Clin.
Endocrinol. Metab. 1999, 84, 2557-2562.
10. Duntas L.H.,Mantsou E. Differences in the adiponektin levels in patients with Graves and eye disease // Eur. Thyroid Ass. Ann. Meet. 18-22 October, 2003, 147.
11. Wakelkamp I.M., Bakker O. et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves ophtalmopathy patients // Clin. Endocrinol.
2003, 58, 280-287.
12. Vaida B., Imrie H. Cytotoxic T-lymphocyte antigen 4 (CTLA4) gene polymorphism confers susceptibility to thyroid assotiated orbitopathy // Lancet. 1999, 354, 743-744.
13. Lantz M., Vondrichova T. et al. Overexpression of immediate early genes in active Graves ophtalmopathy // J. Clin. Endocrinol. Metab. 2005, 90, 4784-4791.
14. Noth D., Gebauer M., Mtiller B. et al. Grave’s ophtalmopathy: natural history and treatment outcomes // Swiss. Med. Wkly. 2001, 131, 603-609.
15. Bartalena L., Marcocci C., Bogazzi F. et al. Relationship between therapy for hyperthyreoidism and the course of Grave’s disease ophtalmopathy // N. Engl. J. Med. 338, 73-78.

Downloads

Download data is not yet available.